Perineural invasion/lymphovascular invasion double positive predicts distant metastasis and poor survival in T3–4 oral squamous cell carcinoma

Kuan-Chung Ting1,4, Tsung-Lun Lee1, Wing-Yin Li3, Chia-Fan Chang1, Pen-Yuan Chu1, Yi-Fen Wang1 & Shyh-Kuan Tai1,2,4

Postoperative adjuvant therapy has been indicated by advanced T classification for T3–4 oral squamous cell carcinoma (OSCC) and the significance of perineural invasion (PNI) and lymphovascular invasion (LVI) in treatment for T3–4 OSCC remains unclear. Ninety-eight cumulative patients with T3–4 OSCC who underwent curative surgery between Jan 2002 and Dec 2010 were recruited and analyzed. Twenty-seven (27.6%) patients were PNI/L VI double positive. PNI/L VI double positive demonstrated independent predictive values for higher neck metastasis (LN+), higher distant metastasis (DM) and low 5-year disease-specific survival (DSS) rates \((p<0.001, \ p=0.017, \ \text{and} \ p<0.001, \ \text{respectively})\) after controlling for other pathologic features of the primary tumors. A high DM rate of 33.3% was noted in PNI/L VI double-positive patients. Among the PNI/L VI double negative, single positive to double positive subgroups, increasing LN+, DM rates and decreasing DSS rate were observed. Among the 44 LN+ patients, PNI/L VI double positive remained associated with a markedly high DM rate of 42.9% and a poor 5-year DSS of 27.7%. PNI/L VI double positive plays important roles in prognostication and potential clinical application for T3–4 OSCC by independently predicting LN+, DM, and poor DSS, and can be used as a good marker to select DM high-risk patients for novel adjuvant therapy trials.

Oral squamous cell carcinoma (OSCC) is the most common type of head and neck cancer1 and the fourth common male cancer death in Taiwan. Surgery is the mainstay of treatment for OSCC, and pathologic features are commonly used for risk group stratification and treatment decision. Perineural invasion (PNI) and lymphovascular invasion (LVI) are two pathologic features representing the consequence of tumor microenvironment interactions. They are established poor prognostic factors in many human malignancies2–6. In OSCC, either PNI or LVI has been shown to correlate with advanced tumor stage, neck metastasis and poor survival6–10, and are two required elements in standard pathology report for OSCC11. In the National Comprehensive Cancer Network guidelines, both PNI and LVI are adverse pathologic features indicating the need for postoperative adjuvant therapy12.

T1–2 OSCC can be treated by single modality of surgery, and adjuvant therapy is generally not indicated in the absence of neck metastasis or adverse pathologic features13–15. Compared with T1–2 OSCC, T3–4 OSCC generally has a higher neck metastasis rate and poor prognosis, and aggressive combination treatment of surgery and postoperative radiotherapy (PORT) or chemoradiotherapy (POCCRT) is frequently required16,17. The advanced T classification has already been regarded as one adverse feature for treatment decision in treatment guidelines12, although pathologic features, such as PNI and LVI, appear at a much higher frequency in T3–4 OSCC8,19. Thus, the significance and clinical application of PNI and LVI in the treatment decision for T3–4 OSCC remain unclear.

Most studies of PNI and LVI in OSCC included patients of all T classifications6–10. Many recent studies, including ours, have focused on the role of PNI or LVI in early T1–2 OSCC20–24, but few studies have focused on T3–4 OSCC which has more aggressive clinical courses and poor prognosis. This retrospective study aimed
to investigate the role of pathologic features of primary tumor, particularly PNI and LVI, in T3–4 OSCC and explore their potential clinical applications.

**Results**

**Patient characteristics.** Of the 98 T3–4 OSCC patients, 93 were male and 5 were female, with a mean age of 54 years (range 32–91 years). The clinicopathologic features are summarized in Table 1. The buccal mucosa (34.7%) and tongue (29.6%) were the two most common primary subsites. Twenty-eight (28.6%) patients were classified as pT3 and 70 (71.4%) as pT4. Positive margin was noted in 20 (20.4%) patients. With a mean tumor thickness 14 mm as the cutoff, 60 (61.2%) patients were classified as having thick tumors (> 14 mm). PNI was identified in 44 (44.9%) patients, and the same incidence of 44.9% was also noted for LVI. Fifty-five (56.1%) patients received postoperative adjuvant therapy. The mean follow-up time for surviving patients is 54.9 months (range 8–166 months).

| Variables                  | No. (%) | 5-year DSS rate (%) | p*    |
|----------------------------|---------|---------------------|-------|
| Subsite                    |         |                     |       |
| Buccal                     | 34 (34.7) | 75.2                | 0.603 |
| Tongue                     | 29 (29.6) | 61.8                |       |
| Gum                        | 19 (19.4) | 72.1                |       |
| Hard palate                | 8 (8.2)  | 66.7                |       |
| Others                     | 8 (8.1)  | 80.0                |       |
| pT classification          |         |                     | 0.325 |
| T3                         | 28 (28.6) | 79.6                |       |
| T4                         | 70 (71.4) | 67.2                |       |
| pN classification          |         |                     | < 0.001|
| N0                         | 54 (55.1) | 88.5                |       |
| N1                         | 6 (6.1)  | 60.0                |       |
| N2                         | 38 (38.8) | 47.6                |       |
| Resection margin           |         |                     | 0.064 |
| Non-positive               | 78 (79.6) | 75.1                |       |
| Positive                   | 20 (20.4) | 54.1                |       |
| Tumor thickness            |         |                     | 0.044 |
| 0–14 mm                    | 38 (38.8) | 83.8                |       |
| >14 mm                     | 60 (61.2) | 63.2                |       |
| Differentiation            |         |                     | 0.489 |
| Well                       | 77 (78.6) | 71.5                |       |
| Moderate to poor           | 21 (21.4) | 68.8                |       |
| PNI                        |         |                     | 0.002 |
| No                         | 54 (55.1) | 82.8                |       |
| Yes                        | 44 (44.9) | 54.5                |       |
| LVI                        |         |                     | 0.05  |
| No                         | 54 (55.1) | 81.9                |       |
| Yes                        | 44 (44.9) | 57.5                |       |
| ENE                        |         |                     | 0.001 |
| Negative                   | 77 (78.6) | 77.0                |       |
| Positive                   | 21 (21.4) | 48.1                |       |
| Adjuvant therapy           |         |                     | 0.015 |
| No                         | 43 (43.9) | 83.4                |       |
| Yes                        | 55 (56.1) | 60.5                |       |
| PORT                       | 21 (21.4) | 82.9                |       |
| POC CRT                    | 34 (34.7) | 47.8                |       |

**Table 1.** Clinicopathologic features of the 98 patients with T3–4 oral squamous cell carcinoma. PNI perineural invasion, LVI lymphovascular invasion, ENE extranodal extension, PORT postoperative radiotherapy, POC CRT postoperative concurrent chemoradiotherapy. *Log-rank test.

Predictors for neck metastasis and oncologic controls. Of the 98 T3–4 OSCC patients, neck metastasis (LN+) was shown in 44 (44.9%). We found that LVI (p = 0.001) and differentiation (p = 0.002) independently predicted LN+ after controlling for PNI, T classification and tumor thickness in multivariate analysis (Table 2). Local recurrence and regional recurrence occurred in 18 (18.4%) and 10 (10.2%) patients, respectively,
impacts by combined PNI/LVI status remained consistent (Table 6). Increasing DM rates were observed from decreasing 5-year DSS rates were also clearly observed (83.3%, 59.3% and 27.7%, respectively). PNI/LVI double negative, single positive to double positive groups (12.5%, 26.7%, and 42.9%, respectively), and particularly worse for the PNI/LVI double positive group (Fig. 2). Notably, in the 44 LN+ patients, the increasing p and DSS survival rates among the three groups were significantly different (p = 0.006 and DM (stratified that PNI/LVI double positive independently predicted significantly worse outcomes for LN+ (p < 0.001), observed from the PNI/LVI double negative, single positive to double positive groups (Table 5). The DM-free 71 (72.4%) patients were classified as non-double positive, including 34 (34.7%) as single positive (either PNI or LVI) and 37 (37.8%) as double negative. Univariate analyses demonstrated significant and higher impacts 27.6%) patients with both PNI and LVI were classified as PNI/LVI double positive. The other 25. Tumor thickness was used in this study in place of Cancer (AJCC) staging manual for oral cavity cancers. Compared with T1–2 OSCC, patients with T3–4 OSCC are usually treated more aggressively based on the advanced T classification. Depth of invasion (DOI) was included in the 8th edition of American Joint Committee on Cancer (AJCC) staging manual for oral cavity cancers. Tumor thickness was used in this study in place of DOI. LN+ was found associated with the development of DM (31.8% vs. 5.6%; p = 0.001). Notably, POCCRT was done at a higher percentage among patients with DM than those without DM (82.4% vs 51.3%, p = 0.017). Trends of higher local recurrence (35.3% vs 14.8%, p = 0.057) and regional recurrence (23.5% vs 7.4%, p = 0.068) rates are also observed among patients with DM. The mean time of DM development was 9.0 months (range 3–24 months), and the mean survival time after DM diagnosis was 3.76 months (range 0–11 months). The 5-year disease-specific survival (DSS) and overall survival (OS) were 70.6% and 62.5%, respectively. Preliminary multivariate analyses were performed for the independent roles of pathologic features of the primary tumors (Table 2). We found that only tumor thickness independently predicted DM (p = 0.026) after controlling for PNI, LVI, T classification, differentiation, and margin. Independent predictors for DSS were PNI (p = 0.010) and LVI (p = 0.049) after controlling for T classification, thickness, differentiation, and margin. In summary, when PNI and LVI were separately considered, PNI predicted a worse DSS, LVI predicted LN+ and a worse DSS, and neither PNI nor LVI predicted DM independently.

Significance of PNI/LVI double positive. Given the inconsistent predictive values of PNI and LVI for LN+, DM and DSS, preliminary multivariate analyses were performed by combining PNI and LVI as one pathologic feature. Twenty-seven (27.6%) patients with both PNI and LVI were classified as PNI/LVI double positive. The other 71 (72.4%) patients were classified as non-double positive, including 34 (34.7%) as single positive (either PNI or LVI) and 37 (37.8%) as double negative. Univariate analyses demonstrated significant and higher impacts by PNI/LVI double positive on LN+ (77.8%), DM (33.3%) and 5-year DSS (44.3%) rates, compared with the impacts by either PNI or LVI (Table 3 and Fig. 1). Importantly, as shown in Table 4, multivariate analyses demonstrated that PNI/LVI double positive independently predicted significantly worse outcomes for LN+ (p < 0.001), DM (p = 0.017) and DSS (p < 0.001) after controlling for other pathologic features of the primary tumors.

Using PNI/LVI double negative as the reference level, increasing LN+, DM and decreasing DSS rates were observed from the PNI/LVI double negative, single positive to double positive groups (Table 5). The DM-free and DSS survival rates among the three groups were significantly different (p = 0.006 and p < 0.001, respectively), particularly worse for the PNI/LVI double positive group (Fig. 2). Notably, in the 44 LN+ patients, the increasing impacts by combined PNI/LVI status remained consistent (Table 6). Increasing DM rates were observed from PNI/LVI double negative, single positive to double positive groups (12.5%, 26.7%, and 42.9%, respectively), and decreasing 5-year DSS rates were also clearly observed (83.3%, 59.3% and 27.7%, respectively).

Discussion
Compared with T1–2 OSCC, patients with T3–4 OSCC are usually treated more aggressively based on the advanced T classification. Depth of invasion (DOI) was included in the 8th edition of American Joint Committee on Cancer (AJCC) staging manual for oral cavity cancers. Tumor thickness was used in this study in place...
of DOI because of the difficulty in retrospective review of tissue sections for DOI. Dirven et al. has reported that tumor thickness can be applied for retrospective survival analyses under incomplete DOI data. The value or significance of pathologic features has not been specifically focused on T3–4 OSCC in previously reported series. Anand et al. reported that PNI was an independent adverse risk factor associated with poor locoregional control and survival in stage III-IV bucco-alveolar complex cancers. Jardim et al. also reported PNI to be an independent predictor for overall survival and disease-free survival in clinical stage III-IV oral tongue and floor of mouth cancers. In this study, we focused on T3–4 OSCC and included more oral cavity subsites. These might explain the different independent impacts of PNI in our data. We observed that many clinicopathologic factors correlated with poor survival outcomes in T3–4 OSCC, such as LN+, tumor thickness, PNI, LVI and extranodal extension (ENE) (Table 1), but most factors of primary tumors did not consistently predict LN+, DM and DSS independently. A possible explanation is that the combined influences of coexisting unfavorable factors in larger T3–4 OSCC tumors might result in the loss of independent predictive roles of individual pathologic features. Therefore, the application and significance of pathologic features in T3–4 OSCC is different from T1–2 OSCC and require special considerations.

The concept of combining poor risk factors in head and neck squamous cell carcinoma (HNSCC) has been reported. The rationale of combining PNI and LVI in this study is that they are both pathologic features of the primary tumor that are related to tumor-microenvironmental interactions. Despite being less well understood, PNI has been considered a process of cancer spread distinct from LVI. Both PNI and LVI data are widely available being two required components in pathologic reports of OSCC. The role of PNI in predicting neck metastasis in early T1–2 OSCC has been reported. We recently reported that the migration ability of OSCC

| Variables | LN+* No. (%) | Distant metastasis* No. (%) | 5-year DSS** |
|-----------|--------------|-----------------------------|-------------|
| PNI       | 18/54 (33.3) | 6/54 (11.1)                | 82.8        |
| No        | 26/44 (59.1) | 11/44 (25.0)               | 54.5        |
| LVI       |              |                            |             |
| No        | 13/54 (24.1) | 5/54 (9.3)                 | 81.9        |
| Yes       | 31/44 (70.5) | 12/44 (27.3)               | 57.5        |
| PNI/LVI   |              |                            |             |
| Non-double positive*** | 23/71 (32.4) | 8/71 (11.3) | 80.2       |
| Double positive | 21/27 (77.8) | 9/27 (33.3) | 44.3       |

Table 3. Univariate analysis of neck metastasis, distant metastasis, and 5-year DSS. LN+ neck metastasis, DSS disease-specific survival, PNI perineural invasion, LVI lymphovascular invasion. *Pearson’s chi-square test or Fisher’s exact test. **Log-rank test. ***Double negative or single positive.

Figure 1. (a) Disease-specific survival curves for PNI/LVI double-positive and non-double-positive groups. (b) Overall survival curves for PNI/LVI double-positive and non-double-positive group.
could be enhanced by human peripheral nerves\textsuperscript{31}, although the exact mechanisms require further investigation. On the other hand, LVI implies the invasion of tumor cells to blood or lymphatic vessels, a process that has long been accepted as an important step in the tumor metastatic cascade or angiogenesis\textsuperscript{32}. Given the distinct metastatic mechanisms of PNI and LVI, our results suggest that combined consideration of PNI and LVI consistently contributes to independent predictive roles for LN+, DM and DSS in T3–4 OSCC.

A lower incidence of DM approximately 10% has been reported for OSCC than for other HNSCC\textsuperscript{33,34}. However, our data demonstrated a higher DM rate of 17.3% in an exclusive T3–4 OSCC cohort despite that POCCRT was done at significantly higher percentage among patients who developed DM. Moreover, the 52.9% isolated DM rate was also higher than the reported data\textsuperscript{34}. In consistent with previous reports, most DM developed in the lung and occurred early within 2 years after treatment completion in our study. The short mean survival time of 3.76 months after DM diagnosis implies again that DM of OSCC is mostly not salvageable\textsuperscript{35,36}. Thus, strategies of prediction and early management of patient high risk for DM before clinical presentation might be important to improve the survival for OSCC. We have reported the value of chest CT especially during follow-up period every 6 months for the first 2 years in high-risk HNSCC patients\textsuperscript{37}. Our results thus suggest that PNI/LVI double positive is another high-risk factor indicating the need of chest CT follow-up after treatment completion.

| Variable | p     | HR    | 95% CI     | LN+* |
|----------|-------|-------|------------|------|
| PNI/LVI double positive (double vs. not double) | < 0.001 | 9.44 | 3.12–28.59 |      |
| pT classification (T4 vs. T3) | 0.993 | 1.01 | 0.35–2.89 |      |
| Tumor thickness (> 14 mm vs. ≤ 14 mm) | 0.204 | 1.87 | 0.71–4.94 |      |
| Differentiation (moderate to poor vs. well) | 0.004 | 5.71 | 1.75–18.59 |      |

| Variable | p     | HR  | 95% CI     | DM* |
|----------|-------|-----|------------|-----|
| PNI/LVI double positive (double vs. not double) | 0.017 | 4.48 | 1.32–15.28 |      |
| pT classification (T4 vs. T3) | 0.618 | 1.45 | 0.34–6.30 |      |
| Tumor thickness (> 14 mm vs. ≤ 14 mm) | 0.015 | 14.07 | 1.67–118.76 |      |
| Differentiation (moderate to poor vs. well) | 0.259 | 2.37 | 0.53–10.54 |      |
| Resection margin (positive vs. non-positive) | 0.086 | 3.37 | 0.84–13.46 |      |

| Variable | p     | HR    | 95% CI     | DSS** |
|----------|-------|-------|------------|-------|
| PNI/LVI double positive (double vs. not double) | < 0.001 | 4.44 | 1.92–10.26 |      |
| pT classification (T4 vs. T3) | 0.618 | 1.45 | 0.34–6.30 |      |
| Tumor thickness (> 14 mm vs. ≤ 14 mm) | 0.015 | 14.07 | 1.67–118.76 |      |
| Differentiation (moderate to poor vs. well) | 0.259 | 2.37 | 0.53–10.54 |      |
| Resection margin (positive vs. non-positive) | 0.086 | 3.37 | 0.84–13.46 |      |

Table 4. Multivariate analyses of independent predictors of primary OSCC for LN+, DM and DSS (PNI and LVI combined). OSCC oral squamous cell carcinoma, PNI perineural invasion, LVI lymphovascular invasion, LN+ neck metastasis, DM distant metastasis, DSS disease-specific survival. *Binary logistic regression. **Cox proportional hazards model.

| PNI/LVI status (n) | No (%) or rate | HR | 95% CI | p  |
|--------------------|----------------|----|--------|----|
| LN+*               |                |    |        |    |
| Double negative (37) | 8 (21.6) | 1  |        |    |
| Single positive (34) | 15 (44.1) | 2.86 | 1.02–8.06 | 0.046 |
| Double positive (27) | 21 (77.8) | 12.69 | 3.83–42.05 | < 0.001 |
| DM*                |                |    |        |    |
| Double negative (37) | 3 (8.1) | 1  |        |    |
| Single positive (34) | 5 (14.7) | 1.95 | 0.43–8.89 | 0.386 |
| Double positive (27) | 9 (33.3) | 5.67 | 1.36–23.59 | 0.017 |
| 5-year DSS**       |                |    |        |    |
| Double negative (37) | 86.7% | 1  |        |    |
| Single positive (34) | 73.7% | 2.43 | 0.73–8.07 | 0.148 |
| Double positive (27) | 44.3% | 6.63 | 2.15–20.40 | 0.001 |

Table 5. LN+, DM and 5-year DSS according to combined PNI and LVI status. PNI perineural invasion, LVI lymphovascular invasion, LN+ neck metastasis, DM distant metastasis, DSS disease-specific survival. *Binary logistic regression. **Cox proportional hazards model.
In recent years, DM has become an important type of treatment failure of OSCC with the improved locoregional control and LVI and LN+ have been demonstrated to be an essential marker for DM. By combining PNI and LVI in this study, the 33.3% DM rate in PNI/LVI double positive patients is even higher than 27.3% in LVI-positive, or 31.8% in LN+ patients. Moreover, the impacts of PNI/LVI double positive specifically in the 44 LN+ patients remained consistent despite not statistically significant for DM due to the small patient number (Table 6). The markedly high DM rate of 42.9% and a poor 5-year DSS of 27.7% in LN+, PNI/LVI double positive patients further support the value of combined PNI/LVI in identifying a high-risk subgroup that require additional adjuvant treatment strategies against DM to improve survival.

Current treatment policy for locally advanced OSCC recommend multimodal treatment, including surgery followed by radiotherapy with or without chemotherapy. However, maintenance adjuvant chemotherapy has not been a standard practice for locally advanced OSCC due to unknown benefit and poor tolerance from toxicities. Recently, metronomic chemotherapy, using oral tegafur-uracil, has been reported to improve survival and reduce DM in stage III-IV OSCC treated by surgery or CCRT. Cetuximab, a monoclonal antibody targeting epidermal growth factor receptor, has also been shown to be a tolerated and effective regimen for maintenance therapy in recurrent metastatic HNSCC. Immune check point inhibitors, such as pembrolizumab for PD-L1 high OSCC, are another type of agents in ongoing clinical trials for maintenance adjuvant therapy in locally advanced HNSCC. For the investigation of the efficacy of these maintenance adjuvant therapies, proper selection of patients at high risk of disease relapse is fundamental in study design.

The major limitation of this study is the relatively small number of T3–4 patients (n = 98) and retrospective study design in our cohort. Another limitation is the use of tumor thickness instead of DOI, which was not

Table 6. DM and 5-year DSS to combines PNI and LVI status in 44 LN+ patients. PNI perineural invasion, LVI lymphovascular invasion, LN+ neck metastasis, DM distant metastasis, DSS disease-specific survival.

| PNI/LVI status | No (%) or rate | HR  | 95% CI       | p   |
|---------------|---------------|-----|--------------|-----|
| DM            |               |     |              |     |
| Double negative | 1 (12.5)      | 1   |              |     |
| Single positive | 4 (26.7)      | 2.55| 0.23–27.71   | 0.443|
| Double positive | 9 (42.9)      | 5.25| 0.54–50.64   | 0.152|
| 5-year DSS    |               |     |              |     |
| Double negative | 83.3%         | 1   |              |     |
| Single positive | 59.3%         | 3.60| 0.43–29.88   | 0.236|
| Double positive | 27.7%         | 7.43| 0.97–57.01   | 0.054|

Figure 2. (a) Kaplan–Meier curves of distant metastasis (DM)-free survival according to PNI/LVI status. The 2-year DM-free survival rates were 90.1%, 83.6%, and 57.2% in PNI/LVI double-negative, single-positive and double-positive group, respectively. (b) Kaplan–Meier curves of disease-specific survival according to PNI/LVI status.
routinely reported during the study period. Also, maintenance adjuvant therapy has not been shown to be beneficial in the literature for OSCC46. Thus, our results cannot advocate this treatment as a standard for PNI/LVI double positive patients. However, our results suggest that PNI/LVI double positive independently predicts DM in T3–4 OSCC and can be a widely available selection marker for DM high-risk patients in future maintenance adjuvant therapy studies.

In conclusion, combined consideration of PNI and LVI is important in prognostication and potential clinical application of T3–4 OSCC. PNI/LVI double positive independently predicts LN+, DM, and poor DSS in T3–4 OSCC, and can be used as a good marker to select DM high-risk patients for future novel adjuvant therapy trials with the goal of reducing DM and improving the survival for T3–4 OSCC.

Materials and methods

**Patient population.** From the hospital database, 467 patients with newly diagnosed OSCC who underwent curative surgery at the Department of Otolaryngology-Head and Neck Surgery, Taipei Veterans General Hospital between Jan 2002 and Dec 2010 were reviewed. The patients were staged according to the 7th edition of the AJCC Cancer Staging Manual. Patients with DM at initial diagnosis, head and neck cancer history, radiation history to the head and neck, or synchronous malignancies were excluded. In total, 98 patients with pT3–4 OSCC were included in the present study. All the patients underwent curative surgery, including neck dissection with or without flap reconstruction. Adjuvant therapy was given following institutional treatment guidelines, particularly to patients with multiple neck metastases, close or positive margin, PNI, LVI, or ENE. Regular follow-up investigations were arranged, including computerized tomography (CT) scan or magnetic resonance imaging of head and neck area every 3 months for first year, 6 months for the second year, and yearly thereafter. Chest radiograph was done yearly. Chest CT was arranged for high-risk patients, including those suspected for recurrence. The medical records were reviewed and updated, and patients or their families were contacted by telephone if lost to follow-up for more than 1 year. This study was reviewed and approved by the Institutional Review Board (IRB No. 2020-09-005BC) of the Taipei Veterans General Hospital. All methods were performed in accordance with the relevant guidelines and regulations. The IRB waived informed consent for this retrospective study.

**Pathologic features.** Pathologic features of the primary OSCC were recorded from the pathology report. The data of DOI was not available during the study period, and tumor thickness was measured from the tumor surface or the ulcer base to the deepest point of invasion. The margins were classified as “positive” or “non-positive.” The “non-positive” margin included dysplasia, close (< 2 mm) or negative margin. A senior pathologist who was blinded to the clinical data re-reviewed all hematoxylineosin stained tissue slides, and special attention was given to PNI and LVI, which were identified throughout the whole area of tumor sections serially under 40× or 100× magnification and were confirmed under 200× magnification. PNI was defined as positive when tumor cell infiltration was identified in any layer of the nerve sheath, or tumor in close proximity involving more than one third of the nerve circumference2. LVI was defined as the detection of tumor cell infiltration in endothelial-lined vessels or tumor nests within or attached to the endothelial cell lining of the lymphovascular space. PNI/LVI double positive indicated the presence of both PNI and LVI in the primary OSCC.

**Statistical analysis.** The endpoints of this study were to evaluate the association between pathologic features and LN+, local and regional control, DM and survival. Comparisons between categorical data were performed using Pearson’s chi-square test or Fisher’s exact test where appropriate, and the independent effect was analyzed using binary logistic regression models. The survival rates, OS and DSS were analyzed by the Kaplan−Meier method. Cox proportional hazards model was used to test the independent significance. Disease-specific death was defined as death either from the index tumor or from treatment-related events. A p value < 0.05 was regarded as statistically significant. All statistical analyses were performed using Statistical Package for Social Sciences software (SPSS v.23 for MAC, SPSS Inc., Chicago, IL).

Received: 16 July 2021; Accepted: 14 September 2021
Published online: 05 October 2021

**References**

1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 68, 394–424 (2018).
2. Liebig, C., Ayala, G., Wilks, J. A., Berger, D. H. & Albo, D. Perineural invasion in cancer: A review of the literature. *Cancer* 115, 3379–3391 (2009).
3. Mohammed, R. A. et al. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. *Am. J. Surg. Pathol.* 31, 1825–1833 (2007).
4. Harris, E. L. et al. Lymphovascular invasion in colorectal cancer: An interobserver variability study. *Am. J. Surg. Pathol.* 32, 1816–1821 (2008).
5. Chatzistefanou, I., Lulek, J., Maradou, K. & Ord, R. A. The role of perineural invasion in treatment decisions for oral cancer patients: A review of the literature. *J. Cranio-maxillofac. Surg.* 45, 821–825 (2017).
6. Jones, H. B. et al. The impact of lymphovascular invasion on survival in oral carcinoma. *Oral Oncol.* 45, 10–15 (2009).
7. Fagan, J. J. et al. Perineural invasion in squamous cell carcinoma of the head and neck. *Arch. Otolaryngol. Head Neck Surg.* 124, 637–640 (1998).
8. Rahima, B., Shingaki, S., Nagata, M. & Saito, C. Prognostic significance of perineural invasion in oral and oropharyngeal carcinoma. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* 97, 423–431 (2004).
9. Michikawa, C. et al. Clinical significance of lymphatic and blood vessel invasion in oral tongue squamous cell carcinomas. *Oral Oncol.* 48, 320–324 (2012).
10. Lanzer, M., Gander, T., Kruse, A., Luebbers, H. T. & Reinisch, S. Influence of histopathologic factors on pattern of metastasis in squamous cell carcinoma of the head and neck. Laryngoscope 124, E160–166 (2014).

11. College of American Pathologists: Cancer Protocols and Checklists: Lip and Oral Cavity, Version 4.0.0.1 (College of American Pathologists, 2018).

12. National Comprehensive Cancer Network. Head and Neck Cancers. Clinical Practice Guidelines in Oncology—v3. http://www.nccn.org/index.asp (2021).

13. Langendijk, J. A. et al. Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time. Int. J. Radiat. Oncol. Biol. Phys. 57, 693–700 (2003).

14. Cooper, J. S. et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 350, 1937–1944 (2004).

15. Bernier, J. et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 350, 1945–1952 (2004).

16. Shah, J. P. & Gil, Z. Current concepts in management of oral cancer—surgery. Oral Oncol. 45, 394–401 (2009).

17. Haddad, R. I. & Shin, D. M. Recent advances in head and neck cancer. N. Engl. J. Med. 359, 1143–1154 (2008).

18. Aivazian, K. et al. Perineural invasion in oral squamous cell carcinoma: Quantitative subcategorisation of perineural invasion and prognostication. J. Surg. Oncol. 111, 352–358 (2015).

19. Miller, M. E. et al. A novel classification system for perineural invasion in noncutaneous head and neck squamous cell carcinoma: Histologic subcategories and patient outcomes. Am. J. Otolaryngol. 33, 212–215 (2012).

20. Tai, S. K. et al. Treatment for T1–2 oral squamous cell carcinoma with or without perineural invasion: Neck dissection and postoperative adjuvant therapy. Ann. Surg. Oncol. 19, 1995–2002 (2012).

21. Tai, S. K., Li, W. Y., Yang, M. H., Chu, P. Y. & Wang, Y. F. Perineural invasion in T1 oral squamous cell carcinoma indicates the need for aggressive elective neck dissection. Am. J. Surg. Pathol. 37, 1164–1172 (2013).

22. Chen, T. C. et al. The impact of perineural invasion and/or lymphovascular invasion on the survival of early-stage oral squamous cell carcinoma patients. Ann. Surg. Oncol. 20, 2388–2395 (2013).

23. Liao, C. T. et al. Identification of a high-risk group among patients with oral cavity squamous cell carcinoma and pT1–2N0 disease. Int. J. Radiat. Oncol. Biol. Phys. 82, 284–290 (2012).

24. Rajappa, S. K. et al. Oncological benefits of postoperative radiotherapy in node-negative early stage cancer of the oral cavity with isolated perineural invasion. Br. J. Oral Maxillofac. Surg. 57, 454–459 (2019).

25. Amin, M. B., Edge, S. B. & Greene, F. L. AJCC Staging Manual 8th edn. (Springer, 2017).

26. Dirven, R. et al. Tumor thickness versus depth of invasion—Analysis of the 8th edition American Joint Committee on Cancer Staging for oral cancer. Oral Oncol. 74, 30–37 (2017).

27. Anand, A. K. et al. Significance of perineural invasion in locally advanced buccal alveolar complex carcinomas treated with surgery and postoperative radiation ± concurrent chemotheraphy. Head Neck 39, 1446–1453 (2017).

28. Jardim, J. F., Francisco, A. L., Gondak, R., Damascena, A. & Kowalski, L. P. Prognostic impact of perineural invasion and lymphovascular invasion in advanced stage oral squamous cell carcinoma. Int. J. Oral Maxillofac. Surg. 44, 23–28 (2015).

29. Lin, Y. T. et al. Triple-positive pathologic findings in oral cavity cancer are related to a dismal prognosis. Laryngoscope 125, E300–E305 (2015).

30. Chatzistefanou, I., Lubej, K., Markou, K. & Ord, R. A. The role of neck dissection and postoperative adjuvant radiotherapy in cN0 patients with PNI-positive squamous cell carcinoma of the oral cavity. Oral Oncol. 50, 753–758 (2014).

31. Lee, T. L. et al. Nerve-tumour interaction enhances the aggressiveness of oral squamous cell carcinoma. Clin. Otolaryngol. 44, 1087–1095 (2019).

32. Guo, W. & Giancotti, F. G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 5, 816–826 (2004).

33. Uchiyama, Y. et al. Distant metastasis from oral cavity-carcinoma correlation between histopathology results and primary site. Oral Radiol. 37, 167–179 (2020).

34. Sumioka, S. et al. Risk factors for distant metastasis in squamous cell carcinoma of the oral cavity. J. Oral Maxillofac. Surg. 71, 1291–1297 (2013).

35. Barros-Silva, P. G. et al. Clinical-pathological and sociodemographic factors associated with the distant metastasis and overall survival of oral cavity and oropharynx squamous cell carcinoma. Med. Oral Patol. Oral Cir. Bucal 25, e375–e382 (2020).

36. Sakamoto, Y. et al. Risk factors of distant metastasis in patients with squamous cell carcinoma of the oral cavity. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 121, 474–480 (2016).

37. Hsu, Y. B. et al. Role of chest computed tomography in head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 134, 1050–1054 (2008).

38. Crucchiolo, J. R. et al. Patterns of recurrence in oral tongue cancer with perineural invasion. Head Neck 40, 1287–1295 (2018).

39. Aieres, F. T., Lin, C. S., Matos, L. L., Kulcsar, M. A. V. & Cernea, C. R. Risk factors for distant metastasis in patients with oral cavity squamous cell carcinoma undergoing surgical treatment. ORL J. Otorhinolaryngol. Relat. Spec. 79, 347–355 (2017).

40. Bugshan, A. & Farooq, I. Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. F1000Res 9, 229 (2020).

41. Huang, W. Y., Ho, C. L., Chao, T. Y., Lee, J. C. & Chen, J. H. Oral tegafur-uracil as a metronomic therapy in stage IVa and IVb cancer of the oral cavity. Am. J. Otolaryngol. 42, 103156 (2021).

42. Hsieh, M. Y., Chen, G., Chang, D. C., Chien, S. Y. & Chen, M. K. The impact of metronomic adjuvant chemotherapy in patients with advanced cancer. Ann. Surg. Oncol. 25, 2091–2097 (2018).

43. Addeo, R. et al. Maintenance therapy with biweekly cetuximab: Optimizing schedule can preserve activity and improves compliance in advanced head and neck cancer. Oncology 95, 353–359 (2018).

44. Vermorken, J. B. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116–1127 (2008).

45. Machiels, J. P. et al. Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-142. Future Oncol. 16, 1235–1243 (2020).

46. Pignon, J. P., Le Maitre, A., Maillard, E. & Bourhis, J. Meta-analysis of chemotherapy in head and neck squamous cell carcinoma (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 92, 4–14 (2009).

Acknowledgements
The authors thank the Clinical Research Core Laboratory, Taipei Veterans General Hospital, for technical assistance. This work was supported in part by Ministry of Science and Technology of Taiwan (Grant Number MOST 108-2314-B-010-046-MY3), and Taipei Veterans General Hospital (Grant Numbers V110C-032).

Author contributions
Conception and design: K.C.T and S.K.T. Development of methodology: W.Y.L, T.L.L, C.F.C, P.Y.C, Y.F.W, and S.K.T. Technical or material support: W.Y.L, T.L.L, C.F.C, P.Y.C, Y.F.W, and S.K.T. Data collection, statistical
review and manuscript drafting: K.C.T. Data verification, statistical review and manuscript revision: S.K.T. All authors have read and agreed to the published version of the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Correspondence and requests for materials should be addressed to S.-K.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021